Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.68 |
| ▸ | GRK2 | P25098 | 1/20 | 0.57 |
| ▸ | GRK5 | P34947 | 1/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.42 |
| ▸ | CDK9 | P50750 | 9/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-1326255A SCHEMBL2205722 | 0.93 | IGF1R (0.67) | IGF1RGRK2GRK5CCNT1CDK9 | |
| SCHEMBL2204780 | 0.91 | IGF1R (0.56) | IGF1RGRK2GRK5FLT4PTK2 | |
| SCHEMBL2205730 | 0.88 | IGF1R (0.52) | IGF1RGRK2GRK5 | |
| SCHEMBL2206560 | 0.87 | IGF1R (0.51) | IGF1RGRK2GRK5CCNT1CDK9 | |
| SCHEMBL2209276 | 0.85 | IGF1R (0.56) | IGF1RGRK2GRK5CCNT1CDK9 | |
| SCHEMBL2209493 | 0.85 | IGF1R (0.48) | IGF1RGRK2GRK5FLT4PTK2 | |
| SCHEMBL2204456 | 0.83 | IGF1R (0.46) | IGF1RGRK2GRK5CCNT1CDK9 | |
| SCHEMBL2204487 | 0.83 | IGF1R (0.54) | IGF1RGRK2GRK5CCNT1CDK9 | |
| SCHEMBL2206429 | 0.83 | IGF1R (0.68) | IGF1RGRK2GRK5CCNT1CDK9 | |
| SCHEMBL2205759 | 0.81 | IGF1R (0.49) | IGF1RGRK2GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | IGF1R 1/4885GRK2 125/4885GRK5 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.